Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug cocktail aims to fight tough head and neck cancers

NCT ID NCT04643379

Summary

This study is testing a combination of three drugs—olaparib, pembrolizumab, and carboplatin—as the first treatment for people with advanced head and neck cancer that has returned or spread. The goal is to see if this three-drug combination leads to more patients seeing their tumors shrink compared to a standard two-drug treatment. The trial will enroll about 30 adults with incurable disease who have not yet received treatment for their advanced cancer.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Washington University School of Medicine

    St Louis, Missouri, 63110, United States

Conditions

Explore the condition pages connected to this study.